TIMELINE OF ACCOMPLISHMENTS

Jupiter Biomedical Research, Inc. (JBR) incorporated with Florida Secretary of State
Dr. Tucker assigns patents for Viright (cancer treatment drug) and Avir (multiple sclerosis treatment drug) to Jupiter Biomedical Research, Inc.
Dr. Tucker signs Work for Hire Agreement assigning all of his present and future work to Jupiter Biomedical Research, Inc.

Sister company, Jupiter Biomedical Research, Inc. is formed in Canada to take advantage of SRED incentive program which provides partial rebates for research and development costs spent in Canada.
Research initiated on clinical development candidates Viright and Avir.
JBR begins first round of financing
JBR contracts with Dr. David Vaughan
JBR signs the first of a series of contracts with Nucro-Technics for experiments with Viright in support of the Efficacy Testing
JBR signs agreement with CanAm Bioresearch, Inc. to synthesize and deliver compound for Viright.
Canadian patents assigned to JRB by Dr. Tucker.
JBR signs agreement with Piramal Enterprises Limited for manufacture of Viright
JBR begins second round of financing
Pharmacokinetics of intravenous and intraperitoneal dose administrations and dose range finding studies in rodents were completed. In vitro cytotoxicity assays using U87 glioblastoma cells Human Lung Carcinoma (A-549) and Mouse Fibroblast (L929) cells.

JBR signs a Master Services Agreement with Charles River Laboratories, Inc.
Comparative Cytotoxicity (cell killing) experiments with U87 glioblastoma cells were conducted and the concentration of Viright required to kill 50% of the cells (IC50) was used as the standard measure of activity. The observed IC50 for Viright was 0.2 mg/mL. For reference, temozolomide (indicated for glioblastoma brain cancer) when tested in similar cell assays had in vitro cytotoxicity IC50’s >4.9 mg/ml, showing substantially higher effectiveness for Viright.

JBR signs agreement for Formulation and Stability Study with BioConvergence LLC dba Signota Solutions
JBR signs Master Services Agreement with Veristat, LLC

Final preparations for Health Canada Clinical Trial Application (CTA) are nearing completion including scaling up of the clinical batch of intravenous drug product for use in the initial Phase 1 human trial.